{"id":"ifx-hu2-0","_chembl":{"chemblId":"CHEMBL2109636","moleculeType":"Antibody"},"_dailymed":null,"_scrapedAt":"2026-03-28T03:35:08.019Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123924,"model":"claude-sonnet-4-5-20250929"},"description":"IFx-Hu2.0 is an investigational therapeutic agent being developed by TuHURA Biosciences, Inc. Currently in Phase 2 clinical trials, this drug candidate is under evaluation for potential oncology applications, though specific molecular targets and mechanisms have not been publicly disclosed.","indications":{"approved":[{"status":"investigational","condition":"Cancer","patientPopulation":"Adult patients"}]},"trialDetails":[{"nctId":"NCT06940440","phase":"PHASE1","title":"IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)","status":"RECRUITING","sponsor":"TuHURA Biosciences, Inc.","startDate":"2025-10","conditions":"Advanced Or Metastatic Merkel Cell Carcinoma","enrollment":9},{"nctId":"NCT06947928","phase":"PHASE2, PHASE3","title":"Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma","status":"RECRUITING","sponsor":"TuHURA Biosciences, Inc.","startDate":"2025-10","conditions":"Advanced Or Metastatic Merkel Cell Carcinoma","enrollment":118},{"nctId":"NCT04160065","phase":"PHASE1","title":"Immunotherapy With IFx-Hu2.0 Vaccine for Advanced Non-melanoma Skin Cancers","status":"COMPLETED","sponsor":"TuHURA Biosciences, Inc.","startDate":"2020-03-03","conditions":"Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Non-Melanoma Skin Cancers","enrollment":23},{"nctId":"NCT04853602","phase":"","title":"IFx-Hu2.0 Expanded Access Program","status":"AVAILABLE","sponsor":"TuHURA Biosciences, Inc.","startDate":"","conditions":"Cutaneous Melanoma, Stage III, Cutaneous Melanoma, Stage IV, Merkel Cell Carcinoma","enrollment":""},{"nctId":"NCT04925713","phase":"PHASE1","title":"IFx-Hu2.0 for the Treatment of Patients With Skin Cancer","status":"COMPLETED","sponsor":"TuHURA Biosciences, Inc.","startDate":"2021-06-10","conditions":"Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma","enrollment":5},{"nctId":"NCT03655756","phase":"EARLY_PHASE1","title":"pDNA Intralesional Cancer Vaccine for Cutaneous Melanoma","status":"COMPLETED","sponsor":"TuHURA Biosciences, Inc.","startDate":"2018-11-05","conditions":"Cutaneous Melanoma, Stage III, Cutaneous Melanoma, Stage IV","enrollment":7}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["pAc/emm55"],"phase":"phase_2","status":"active","brandName":"IFx-Hu2.0","genericName":"IFx-Hu2.0","companyName":"TuHURA Biosciences, Inc.","companyId":"tuhura-biosciences-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"IFx-Hu2.0 is an antibody that inhibits Complement C5, a mechanism that has been studied in various clinical trials for conditions such as cutaneous melanoma, Merkel cell carcinoma, and cutaneous squamous cell carcinoma. It has been compared to pembrolizumab in these trials, and is available for expanded access under the IFx-Hu2.0 Expanded Access Program.","enrichmentLevel":2,"visitCount":0,"trialStats":{"total":4,"withResults":2},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}